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Abstract
Background: The African Programme for Onchocerciasis Control (APOC) was created in 1995 to establish
community-directed treatment with ivermectin (CDTi) in order to control onchocerciasis as a public health
problem in 20 African countries that had 80 % of the global disease burden. When research showed that CDTi
may ultimately eliminate onchocerciasis infection, APOC was given in 2008 the additional objective to determine
when and where treatment can be safely stopped. We report the results of epidemiological evaluations
undertaken from 2008 to 2014 to assess progress towards elimination in CDTi areas with ≥6 years treatment.
Methods: Skin snip surveys were undertaken in samples of first-line villages to determine the prevalence of O.
volvulus microfilariae. There were two evaluation phases. The decline in prevalence was evaluated in phase 1A.
Observed and model-predicted prevalences were compared after correcting for endemicity level and treatment
coverage. Bayesian statistics and Monte Carlo simulation were used to classify the decline in prevalence as faster
than predicted, on track or delayed. Where the prevalence approached elimination levels, phase 1B was launched
to determine if treatment could be safely stopped. Village sampling was extended to the whole CDTi area. Survey
data were analysed within a Bayesian framework to determine if stopping criteria (overall prevalence <1.4 % and
maximum stratum prevalence <5 %) were met.
Results: In phase 1A 127 665 people from 639 villages in 54 areas were examined. The prevalence had fallen
dramatically. The decline in prevalence was faster than predicted in 23 areas, on track in another 23 and delayed in eight
areas. In phase 1B 108 636 people in 392 villages were examined in 22 areas of which 13 met the epidemiological criteria
for stopping treatment. Overall, 32 areas (25.4 million people) had reached or were close to elimination, 18 areas (17.4
million) were on track but required more years treatment, and in eight areas (10.4 million) progress was unsatisfactory.
Conclusions: Onchocerciasis has been largely controlled as a public health problem. Great progress has been made
towards elimination which already appears to have been achieved for millions of people. For most APOC countries,
nationwide onchocerciasis elimination is within reach.
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Background
Onchocerciasis has been an important public health
problem in tropical Africa, Latin America, and the
Yemen with over 40 million people infected before the
launch of large-scale control and an at-risk population
of over 160 million of which more than 99 % live in
Africa [1–4]. Thirty-one countries in Africa - 20 which
are participating countries of the African Programme for
Onchocerciasis Control (APOC) [5] and 11 which were
members of the previous Onchocerciasis Control
Programme in West Africa (OCP) [6] - were known or
suspected to be endemic for onchocerciasis [1]. Human
onchocerciasis is caused by the filarial parasitic nema-
tode Onchocerca volvulus which is transmitted through
repeated bites by blackflies of the genus Simulium. It is
the world’s second leading infectious cause of blindness
and the disease is also known as river blindness because
the blackfly that transmits the parasite lives and breeds
near fast-flowing streams and rivers. In addition to ocu-
lar complications, onchocerciasis causes skin disease, in-
cluding unsightly skin lesions and debilitating itching,
excess mortality among highly infected people and it is
also a major risk factor for epilepsy and nodding
syndrome [7–10]. Due to its negative impact on health,
social well-being and productivity, onchocerciasis per-
petuates poverty and under-development [11].
The Onchocerciasis Control Programme in West
Africa (OCP) started large scale control of onchocercia-
sis in 1974 through vector control, using aerial spraying
of environmental safe larvicides [6]. This strategy was
later complemented by ivermectin mass treatment of the
at-risk population following the donation of ivermectin
in 1987 [12]. At its closure by the end of 2002, OCP had
successfully eliminated the disease as a public health and
socio-economic problem in all 11 OCP countries except
Sierra Leone where control activities were interrupted
because of civil unrest [13]. Ivermectin proved to be very
safe and highly effective against microfilariae (mf) which
cause the severe manifestations of the disease [14, 15],
and community-directed treatment with ivermectin
(CDTi) was proven to be an effective and sustainable
strategy for annual treatment of the eligible population
in endemic communities [16, 17]. CDTi was adopted as
the mainstay of onchocerciasis control in APOC-
supported countries. APOC was initiated in 1995 with
the ultimate goal of controlling onchocerciasis as a pub-
lic health problem in those African countries not cov-
ered by the OCP and which had more than 80 % of the
global burden of onchocercal disease [4, 5, 18].
The APOC partnership has helped onchocerciasis en-
demic countries to successfully extend CDTi coverage
from 1.5 million in 1997 to over 112 million people in
2014, when ivermectin reached over 180 000 communi-
ties in Africa [19]. It has enabled treatment of approxi-
mately 76 % of the total population at risk including
several countries affected by security issues. Annual
CDTi has conferred enormous clinical benefits, averting
the loss of 2 million Disability-adjusted Life Years every
year at a cost of only US$27 per Disability-adjusted Life
Year averted, making it very cost-effective [20].
Both OCP and APOC were set up with the objective
to control the disease as a public health problem rather
than to achieve elimination of the infection and trans-
mission. At the time it was considered doubtful that
elimination could be achieved with ivermectin alone and
a conference on the eradicability of onchocerciasis con-
cluded that elimination would be possible in most of the
Americas where onchocerciasis foci are often small and
circumscribed, and several (though not all) vector spe-
cies are relatively inefficient, but that there remained
considerable uncertainty as to whether ivermectin treat-
ment could ever achieve sustained interruption of trans-
mission in Africa where onchocerciasis is endemic over
vast areas and where all vectors are highly efficient [21].
However, subsequent longitudinal studies were able to
show the feasibility of elimination of onchocerciasis in
some African setting using only ivermectin treatment. In
early 2000s, a detailed review of the impact of ivermectin
treatment on onchocerciasis infection in the OCP coun-
tries showed that prevalence of infection had fallen to
very low levels after 10–12 years of treatment in oncho-
cerciasis foci in the Western extension area where there
had never been vector control [22]. In 2005 a longitu-
dinal study was started in three initially hyperendemic
onchocerciasis foci in Mali and Senegal where ivermec-
tin had been given for 15–17 years at annual (two foci)
and 6-monthly (one focus) intervals. The aim of the
study was to undertake a detailed assessment of residual
levels of infection and transmission and to test whether
ivermectin treatment could be safely stopped. In all
three foci the epidemiological and entomological indica-
tors were below or close to provisional thresholds [23].
Treatment was then stopped and follow-up data over a
period of 3 to 5 years showed no evidence of new infec-
tion or transmission [24]. This study provided the first
evidence that annual or 6-monthly ivermectin treatment
can eliminate onchocerciasis infection and transmission,
and that treatment can be safely stopped. Subsequent
evidence from epidemiological evaluations in APOC
countries also showed that infection levels had fallen to
insignificant levels in some areas. Parasitological surveys
based on skin snips examination undertaken in 2008 in
two onchocerciasis endemic foci with annual ivermectin
Tekle et al. Infectious Diseases of Poverty  (2016) 5:66 Page 2 of 25
treatment in Kaduna State, Nigeria showed that the preva-
lence of mf was zero in all 27 surveyed villages [25].
In response to these new findings, the Joint Action
Forum of APOC approved in 2008 an additional object-
ive for the programme “to determine when and where
ivermectin treatment can be safely stopped and to pro-
vide guidance to countries on preparing to stop ivermec-
tin treatment where feasible”.
An international group of experts was convened in
early 2009 to review the state-of-the-art and identify
critical issues for onchocerciasis elimination in Africa
[26]. The experts defined onchocerciasis elimination op-
erationally as “the reduction of onchocerciasis infection
and transmission to the extent that interventions can be
stopped, but post-intervention surveillance is still neces-
sary”. They recommended that APOC proceed gradually,
targeting elimination where considered feasible and
undertaking a critical evaluation of the epidemiological
and operational situation in countries before adopting
the goal of elimination. Building on the report of the
expert group, APOC developed a conceptual and
operational framework of onchocerciasis elimination
that was further refined by the Technical Consultative
Committee of APOC [27]. The conceptual framework
document includes a description of the main operational
phases in elimination and the evaluation methods and
indicators to be used in each phase.
Following the approval of the new objective on oncho-
cerciasis elimination, APOC has conducted a series of
epidemiological evaluation surveys from 2008 to date.
This article presents the results of the epidemiological
evaluation surveys and a comprehensive analysis of the
survey data collected between 2008 and 2015 in 12
APOC countries, showing the decline in onchocerciasis
infection levels and estimates of the number of people
freed from the risk of onchocerciasis infection. As
APOC closed on December 31, 2015, this paper will also
serve to indicate the status of all CDTi projects evalu-
ated in the last 6–7 years and provide a basis for future
decision making by the endemic countries on where and
when to stop ivermectin treatment.
Methods
Conceptual framework of onchocerciasis elimination
Figure 1 illustrates APOC’s conceptual framework for
onchocerciasis elimination [27]. After the first round of
ivermectin treatment in an onchocerciasis focus, the in-
tensity of infection in the community (expressed using
the community microfilarial load, CMFL [28]) declines
dramatically, and this translates into a significant drop
in transmission. After each subsequent treatment round,
the mean microfilarial load is further reduced and the
annual level of transmission continues to decline. The
adult worm population also shows a decline, although
much more slowly, due to natural or treatment-induced
death or sterilisation of old worms. This continues till
the fertile adult worm population has been reduced to
such low levels that it will move irreversibly to its ex-
tinction, even without further ivermectin treatment. The
parasite density is said to have fallen below its “break-
point” and ivermectin treatment can be stopped, signal-
ling the end of the intervention phase 1. The concept of
a breakpoint is operationally important: it means that in-
fection and transmission do not have to be completely
zero before treatment can be safely stopped. Breakpoints
are predicted by models [29, 30] and confirmed
Fig. 1 Conceptual framework for onchocerciasis elimination
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empirically: in the proof-of-concept study in Mali and
Senegal there were still several mf positive people in
each of the three river basins but when treatment was
stopped, there was no renewed transmission and infec-
tion [24]. The duration of phase 1 varies according to
initial endemicity level and treatment coverage. The
evaluation in this phase has two sequential objectives: (i)
to evaluate the progress towards elimination by assessing
the decline in infection levels in the human population
towards provisional thresholds for elimination (evalu-
ation phase 1A), and (ii) to confirm, using both para-
sitological and entomological indicators, that the
provisional threshold has been reached and that treat-
ment can be safely stopped (evaluation phase 1B at
the end of phase 1).
In phase 2 the parasite numbers in the human and
vector populations are so low that any residual transmis-
sion is expected to be insufficient for the parasite popu-
lation to survive on the long term. Active surveillance
including both entomological and epidemiological indi-
cators is needed to make sure that there is no recrudes-
cence of the parasite population and transmission. If no
recrudescence is detected over a period of at least
3 years, the area is expected to have met or to be moving
inevitably to meet the general definition of elimination
of an infectious disease: ‘reduction to zero of the inci-
dence of infection caused by a specific agent in a defined
geographical area as a result of deliberate efforts; contin-
ued measures to prevent reestablishment of transmission
are required’ [31]. The area then moves into phase 3
with routine surveillance to detect possible reintroduc-
tion of infection from other areas where the infection
still occurs.
Evaluation areas
In this article we report the results of epidemiological
evaluations undertaken during phase 1. Since its incep-
tion, APOC has provided support to the establishment
of sustainable annual CDTi in 106 CDTi projects that
covered nearly all endemic areas in the APOC countries
where onchocerciasis was a public health problem. Be-
tween 2008 and 2015, epidemiological evaluations were
undertaken in 52 CDTi projects which had benefited
from at least 6 years of annual ivermectin treatment.
Most of these CDTi projects cover the onchocerciasis
endemic area within the boundaries of an administrative
unit of the health system that is responsible for the local
implementation of CDTi, usually the health district, and
where treatment was introduced at approximately the
same time in all villages. Most of these projects were
considered sufficiently homogeneous in terms of epi-
demiology and intervention history to include them as
evaluation areas for the current analysis. However, in
two countries, Chad and the Central African Republic,
there is only one CDTi project for the whole country
covering a wide range of endemic areas over a distance
of 700 and 1400 km respectively and with many years
difference in the start of treatment. The CDTi projects
for these two countries were therefore divided into sub-
projects according to implementation unit of the health
system, and these subprojects were used as evaluation
areas in the current study. Furthermore, there were two
situations (Edo and Ondo States in Nigeria and Keffa,
Sheka and Bench-Maji zones in Ethiopia) where the
evaluation was done in an endemic focus that ran across
the border of neighbouring CDTi projects and these
projects were combined into one evaluation area. In all
other cases, the evaluation area corresponds to the CDTi
project area, as defined by APOC.
Data for the target population and number of people
treated in each evaluation area were obtained from the
annual technical reports from each CDTi project to
APOC. Treatment coverage was calculated as the per-
centage of the total population (≥0 years old) in the
CDTi project area that was treated in a given year. For
project areas where mass drug administration with iver-
mectin had been undertaken during years before the es-
tablishment of the APOC project an attempt was made
to collect data on start year of treatment, number of
years of treatment and treatment coverage from the
Ministry of health and/or a non-governmental organisa-
tion that supported those early treatments. However,
these data are less complete than those for the APOC
period. A treatment coverage of less than 60 % was con-
sidered inadequate and years with such low coverage
were not taken into account in the calculation of the
number of years of ivermectin treatment of an evalu-
ation area.
Phase 1A evaluation
Objective
This is the evaluation activity for most of the phase 1
period. It involves parasitological surveys after at least
6 years of ivermectin treatment to assess the remaining
levels of O. volvulus infection in a sample of communi-
ties from an endemic focus and to compare the survey
results with the predicted prevalence in order to deter-
mine whether the decline in prevalence is adequate and
the evaluation area is making satisfactory progress to-
wards elimination. If the survey results show that the
prevalence has already fallen to very low levels ap-
proaching the elimination thresholds, the evaluation area
would move into phase 1B. If the prevalence is still too
high, additional phase 1A surveys would be needed at
intervals of 3 to 4 years. The results reported here con-
cern only the first round of phase 1A surveys under-
taken in APOC countries.
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Sample population
For each evaluation area some ten sample communities
were selected from high risk locations near the river and
potential vector breeding sites in that part of the evalu-
ation area where the pre-control endemicity levels were
highest according to the results of Rapid Epidemiological
Mapping of Onchocerciasis (REMO) [27]. For each sam-
ple village, the geographic coordinates were used to
obtain the local predicted pre-control prevalence of nod-
ules from the REMO map [3].
Parasitological surveys
The parasitological evaluation involved skin snip surveys
to estimate the prevalence and intensity of O. volvulus
infection. All skin-snip surveys were done 11–12 months
after the last ivermectin treatment round (thus just be-
fore the next distribution). In each surveyed village, all
subjects aged 5 years or above who agreed to participate
(or whose parents agree for them to participate in the
case of children) and who voluntarily presented them-
selves at the screening centre for the survey were asked
for identification data (name, age, sex, number of years
resident). In a few surveys that were undertaken before
2011 children between 1 and 5 years of age were also
examined but these results for this age group were ex-
cluded from the current analysis. For villages with less
than 100 examined subjects, the examination results
were combined with those for the nearest village if there
existed such a village at less than 5 km distance. For very
large villages with more than 1000 inhabitants, the sur-
veys were done in a subsection of some 300 inhabitants
that was located closest to the river. The surveys used
established skin-snip examination methods in which the
national onchocerciasis teams had been trained by
APOC [32]. Two skin biopsies were obtained (one from
each iliac crest) of all individuals who presented them-
selves for the survey. A 2 mm Holth corneoscleral punch
(Storz instrument GMBH, Heidelberg, Germany) was
used to obtain the skin biopsies. After each series of two
bloodless skin-snip obtained from a subject, the scleral
punch was sterilized sequentially in sodium hypochlorite
solution, distilled water and then autoclaved by pressure
for 15 minutes. The entire process is to ensure that HIV
and other blood-borne infections are not transferred. In
six evaluation areas where parasitological surveys were
undertaken before 2010, the skin snips were microscop-
ically examined after incubation for 30 min in distilled
water and a further 24 h in saline for negative skin-snips
for the presence and number of O. volvulus mf [32].
From 2010 onwards the 30 min reading was dropped
and all skin snips were microscopically examined after
incubation for 24 h in saline. The numbers of mf were
counted and the results recorded for each person exam-
ined. Information on the migration history for each
person during the last 10 years before the survey was
also collected. Finally, exact geographical coordinates
were taken for each sample village using a GPS.
Comparison with model predictions
The trend in the prevalence of mf after annual ivermectin
treatment depends on the pre-control endemicity level
and the treatment coverage achieved. Hence, the expected
trend in prevalence during the control period will differ
between endemicity levels and this had to be taken into
account in the interpretation of the survey results. This
was done by referring to ONCHOSIM predictions of the
expected trends in prevalence for different pre-control en-
demicity levels and treatment coverage [33, 34]. This
model has been used extensively to support policy making
in onchocerciasis control [34–37] and model-predicted
trends in infection and transmission levels were found to
match well to those observed during onchocerciasis con-
trol after cessation of control activities [24, 38–40].
The comparison of observed trends and model predic-
tions was done in two ways. Firstly, in order to give a gen-
eral appreciation of the observed data for each evaluation
area in relation to predictions, we plotted the observed mf
prevalence for the surveyed villages of each evaluation
area against the predicted trends shown in Fig. 2. Figure 2
shows the predicted trends in the prevalence of mf in en-
demic foci for which the pre-control endemicity levels
range from a very low CMFL of 3 mf/snip (mf/s) to a very
high CMFL of 70 mf/s and a treatment coverage of 75 %
(the average treatment coverage in the evaluation areas).
Assumptions underlying these predicted trends are further
explained in Additional file 2.
The results are shown in three graphs for three differ-
ent ranges of pre-control endemicity levels: high
(CMFL >30mf/s or prevalence of mf >79 %), moderate
(10< CMFL ≤30 mf/s or 61 % < prevalence of mf ≤79 %)
and low (CMFL ≤10 mf/s or prevalence of mf ≤61 %).
For each surveyed village, the pre-control endemicity
level was estimated from the map of the predicted pre-
control prevalence of nodules in APOC countries, and
converted to the prevalence of mf as described in the
statistical classification section below.
Secondly, we undertook a detailed statistical analysis to
compare the observed prevalence for each surveyed village
and each evaluation area with the corresponding model
predictions and classify the decline in prevalence in each
evaluation area as “faster than predicted”, “on track” or
“delayed” after taking the statistical uncertainty in the vari-
ous data sources into account, as explained below.
Statistical classification of the decline in mf prevalence in
an evaluation area
The classification was done in four steps: 1) estimate the
pre-control nodule prevalence in adult males (age 20+)
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from REMO data; 2) translate pre-control nodule preva-
lences in adult males to pre-control mf prevalences in
the general population (age 5+, standardised to the OCP
population); 3) predict the expected mf prevalences at
the time of the phase 1A survey using ONCHOSIM,
given the pre-control mf prevalences from step 2 and
the history of control; and 4) given observed and pre-
dicted mf prevalences at the time of the Phase 1A sur-
vey, calculate the probability that the true decline in
infection levels following onchocerciasis control in the
evaluation area is faster or slower than predicted by
ONCHOSIM. Because each of the four steps involves
uncertainty, we used Monte Carlo simulation to propa-
gate all uncertainty to the final estimate in step 4. Below
we explain each step in more detail.
In the first step, we determined for each surveyed vil-
lage location i the pre-control prevalence of nodules Pre-
nodi in adult males (age 20+). For APOC countries, the
geographic distribution of pre-control endemicity levels
has been previously estimated using a geostatistical ana-
lysis of REMO survey results in 14,473 villages, yielding
a detailed 1 km resolution map of predicted pre-control
prevalence of nodules, including prediction standard
error [3]. Using this map, we defined nodule prevalence
Prenodi as a random variate following a normal distribu-
tion N(μnod,i, σi
2), where μnod,i is the geostatistical predic-
tion of the pre-control prevalence of nodules at location
i, and σi is the corresponding prediction standard error.
For each location i in the evaluation area, we generated
100 000 random draws from the normal distribution
N(μnod,i, σi
2) for use in the second step.
In the second step, we translate pre-control nodule
prevalence Prenodi in adult males to pre-control mf
prevalence Premfi in the general population (age 5+,
standardised to the OCP population). For this conver-
sion, we used a Bayesian statistical model, which has
been previously fitted to village-level data on pre-control
nodule prevalence in adult males and mf prevalence in
the general population from several sites in West and
Central Africa [41]. We accounted for uncertainty in the
conversion from Prenodi to Premfi by drawing random
values from the joint posterior distribution of parameter
values of the conversion model, and using one random
set of parameter values for the conversion of each of the
100 000 draws of Prenodi for each location i from step
one (for further details see Additional file 3).
In step three, we used ONCHOSIM [33, 36] to predict
the mf prevalence in the general population at the time
of the phase 1A survey, given pre-control mf prevalence
Premfi from step 2 and the reported history of control.
First, we simulated trends in village infection levels in
ONCHOSIM for all combinations of a pre-defined set of
pre-control infection levels (CMFL 3, 5, 10, 20, 30, 50
and 70 mf/s) and a set of treatment coverage levels
(60 %, 65 %, 70 %, 75 %, 80 %). More details regarding
methods used and assumptions underlying the ONCH-
OSIM predictions is provided in Additional file 2. By
performing 1 000 repeated stochastic simulations for
each combination, we produced a sample from the dis-
tribution of predicted mf prevalences levels over time.
Then, given a draw of Premfi from step 2 and the dur-
ation and average treatment coverage of CDTi in
Fig. 2 Predicted trends in the prevalence of mf by pre-control endemicity level
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location i, we determined the four closest simulation
scenarios (nearest simulated average pre-control mf preva-
lence below and above Premfi, and nearest simulated
treatment coverage below and above the reported treat-
ment coverage), randomly drew one simulation from each
of the four simulation scenarios, and performed linear
interpolation to produce a draw of Premfi, the predicted
mf prevalence at the time of the Phase 1A survey. This
was repeated for all 100,000 draws for each location i.
Last, in step four, we calculated the difference Di be-
tween the observed and predicted mf prevalences for
each location i and the mean difference D for all sur-
veyed locations in the evaluation area. We then calcu-
lated the probability that the observed decline was lower
or higher than predicted. To do so, we first quantified
the uncertainty in the observed mf prevalence in a
Bayesian framework, assuming a uniform prior for the
unknown true mf prevalence and a binomial likelihood
for the observed data. Under these assumptions, the
posterior distribution of the “true” mf prevalence
Truemfi is a Beta distribution with parameters α = (mi +
1) and β = (ni −mi + 1), where ni is the number of indi-
viduals examined for mf in the surveyed village at loca-
tion i and mi is the number of individuals that were mf
positive [42]. Next, for each of the 100,000 draws of Pre-
dmfi (which include all uncertainty from previous con-
version steps), we drew a random value of Truemfi and
calculated the difference Di between the two, resulting
in 100,000 draws for Di in each location i. Finally we cal-
culated the mean difference over all surveyed locations,
resulting in 100 000 draws for the mean difference D in
the evaluation area.
Using the posterior sample of D, we calculated the prob-
ability pL that D< 0, i.e. that the true mean prevalence of
mf in the surveyed locations is lower than the model-
predicted mean prevalence and the probability pH that
D> 0, i.e. that the true mean prevalence of mf in the sur-
veyed locations is greater than the model-predicted mean
prevalence. The decline in the prevalence of mf in the
evaluation area was subsequently classified as (i) signifi-
cantly faster than predicted (pL >0.975), (ii) delayed: de-
cline significantly slower than predicted (pH >0.975), or
(iii) on track (pL ≤0.975 and pH ≤0.975, i.e. the equal tailed
95 % credible interval for D includes 0).
Phase 1B evaluation
Objective
To confirm that residual infection and transmission
levels are below defined elimination thresholds and that
treatment can be safely stopped, epidemiological and en-
tomological evaluations are needed throughout the
evaluation area. In this article we report the results of
the epidemiological evaluations only. The entomological
evaluations are still ongoing and will be reported at a
later stage.
Sample population
The epidemiological evaluation involved parasitological
surveys using the same skin snip methodology as in
phase 1A. To ensure that there remained no pockets of
infection that could cause recrudescence of transmission
after cessation of treatment, Phase 1B surveys were
planned such that together with the Phase 1A surveys,
they provided complete spatial coverage of all potential
transmission areas in the evaluation unit. The frame-
work document [27] recommends that survey villages
are selected along the main rivers and affluents at a dis-
tance of no more than 20 to 30 km between villages.
During the actual evaluations, the selection of villages
was generally done at shorter distances and the average
distance to the nearest village was 8 km.
Criteria for stopping treatment
The conceptual and operational framework document
defines as the provisional epidemiological criteria for
stopping ivermectin treatment a prevalence of mf <1 %
in 90 % of surveyed villages and <5 % in all surveyed vil-
lages [27]. The provisional entomological criterion was
defined as a vector infectivity rate <0.5 infected fly per 1
000 flies. These criteria were first postulated based on
large-scale experiences with cessation of vector control
over some 500,000 km2 in the OCP countries and
ONCHOSIM predictions [35, 43]. At the time of cessa-
tion of vector control the prevalence of mf in first line
villages was on average 1.4 % with a maximum of 4.8 %
but, as predicted by ONCHOSIM, these residual levels
of infection did not result in recrudescence of transmis-
sion when vector control was stopped [40, 43, 44]. The
postulated criteria were subsequently validated for
ivermectin-based control in the proof-of-principle study
in Mali and Senegal [24] where treatment was stopped
based on these criteria and where there was no recru-
descence of infection and transmission up to 5 years
after cessation of treatment. Based on this empirical evi-
dence, APOC adopted these criteria provisionally for
decision-making on stopping ivermectin treatment but
noted that they should be revised when further evidence
becomes available. Turner et al. [45] and Stolk et al. [29]
refer to these epidemiological criteria as the provisional
Operational Thresholds for Treatment Interruption
followed by Surveillance (pOTTIS) and summarise them
for modelling purposes into an overall microfilaria
prevalence <1.4 % (the weighted mean of the 2 preva-
lence thresholds in the framework document definition).
In our analysis we also use the threshold of 1.4 % for the
overall mf prevalence in the evaluation area. However,
the purpose of the pOTTIS was not only to establish
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that the overall prevalence in the evaluation area was
very low but also to ensure that there remained no sig-
nificant local pockets of infection that could lead to re-
crudescence. We therefore included in our analysis a
second criterion relating to the pOTTIS upper limit
prevalence of 5 % and taking into account the sampling
strategy used. In phase 1B, sample villages to be sur-
veyed were selected at intervals of less than 20 km along
the major rivers and affluents in the evaluation area.
Hence, each selected sample village can be regarded as
representing a river stretch (8 km length on average, i.e.
within the flight range of the vector) and the examined
village population as a sample from the population of
this river stretch. The sampling method used is then a
type of stratified sampling in which each river stretch is
a stratum and the population of a surveyed village a ran-
dom sample of the population of the corresponding
stratum. Our second criterion is that the true prevalence
of mf for each stratum should be below 5 % or, formu-
lated otherwise, that the maximum stratum prevalence
of mf should not exceed 5 %.
Analysis of phase 1B evaluation data
For each evaluation area we assessed whether the two
criteria for stopping treatment were met after taking the
statistical uncertainty in the sample data into account. As
for the Phase 1a data, this was done again using a combin-
ation of Bayesian statistics and Monte Carlo sampling.
For each stratum Sj in an evaluation area, we define the
posterior distribution of the true mf prevalence Pmfj as a
beta distribution with parameters α = (mj + 1) and β = (nj
−mj + 1) [42]. Here, nj is the number of individuals exam-
ined for mf and mj the number of examined individuals
who were mf positive in the survey that was undertaken
in stratum Sj. Next, we generated draws from the posterior
distributions of the true mf prevalence Pmf in the evalu-
ation unit and the true maximum stratum prevalence of
mf Pmax (i.e. the maximum of all J strata in the evaluation
unit) by generating a random value Pmfj from Beta(mj +
1, nj − mj + 1) for each of the J strata, and calculating the
average Pmf ¼ 1J
XJ
j¼1Pmf j
 
and maximum (Pmax =
maxj = 1 : J(Pmfj)) of the J draws of Pmfj. This process was re-
peated 100,000 times to generate probability distributions
of Pmf and Pmax. These probability distributions were sub-
sequently used to calculate the probability that the true area
prevalence of mf Pmf exceeds 1.4 % and the probability that
the maximum stratum prevalence of mf Pmax exceeds 5 %.
Each evaluation area was then classified as having met
the epidemiological criteria for stopping treatment if the
probability of mf prevalence exceeding 1.4 % was under
0.01 and if the probability of the maximum stratum preva-
lence being over 5 % was less than 0.05. Evaluation areas
that did not meet these two criteria were classified as “close
to elimination” if the percentage of mf positives in the total
sample was less than 1.4 % and as “criteria not met” if the
percentage of mf positives was greater than 1.4 %.
Overall classification using all available data from phases
1A and 1B
Finally we used all available data to classify the 58 evalu-
ation areas according to their progress towards elimin-
ation into four categories: i) meets epidemiological
criteria for stopping treatment (same as the phase 1B
classification), ii) close to elimination (all other areas
with overall prevalence <1.4 %), iii) on track but still
some years to go (decline in prevalence equal/faster than
predicted but overall prevalence still >1.4 %) and iv) un-
satisfactory progress (decline in prevalence delayed and
overall prevalence >1.4 %). Table 1 provides for easy
Table 1 Summary of the classifications used for the different phases
Phase (objective) Classification Criteria
Phase 1A (Assess decline in prevalence) Faster decline Prevalence declining significantly faster than predicted
On track Prevalence not significantly different from predicted
Delayed decline Prevalence declining significantly slower than predicted
Phase 1B (Determine if treatment can be stopped) Stopping criteria met Area prevalence significantly below 1.4 % and maximum
stratum prevalence significantly below 5 %
Close to elimination Above thresholds not met but <1.4 % mf positives in
sample
Stopping criteria not met Above thresholds not met and >1.4 % mf positives in
sample
Overall classification using all data (Assess progress
towards elimination)
Stopping criteria met Stopping criteria met in phase 1B
Close to elimination Close to elimination in phase 1B or <1.4 % mf positives in
phase 1A
On track but some time to go Prevalence decline faster/on track and > 1.4 % mf positives
in sample
Unsatisfactory Prevalence decline delayed and > 1.4 % mf positives in sample
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reference a summary of the classifications used for the
different phases.
Implementation of the epidemiological evaluations in
APOC countries
The implementation of the epidemiological evaluation
was the responsibility of the Ministry of Health of each
APOC country in collaboration with its partners in
onchocerciasis control and with technical and financial
support from APOC. Each APOC country has a
National Onchocerciasis Task Force which brings the
various partners together in order to coordinate the on-
chocerciasis control activities in the country. The man-
ager of the National Onchocerciasis Task Force is the
responsible officer for onchocerciasis control in the
Ministry of Health. The National Onchocerciasis Task
Force of each country submitted to APOC a plan of ac-
tion and budget for epidemiological surveys. Upon ap-
proval of this plan, APOC provided the agreed funding
and external experts to train and support national teams
with the implementation of epidemiological evaluation.
All surveys were reportedly undertaken according to
the standard procedures as described in the Epidemio-
logical Evaluation Guide of APOC that is based on the
OCP guide for epidemiological evaluations of onchocer-
ciasis control that has been in use in Africa for more
than four decades [46]. In almost all surveys there was
direct APOC involvement in the actual survey activities
in the field especially during the first years by sending
technical advisors and/or APOC staff for planning, train-
ing and supervision to standardize the quality of the sur-
veys across the countries. All survey results were
reviewed by the Technical Consultative Committee of
APOC, a group of experts who technically advised the
programme. The data was recorded on standard forms
and processed at country and APOC level for data clean-
ing and double data entry before forwarding the data for
analysis.
Results
Results of phase 1A evaluations
Phase 1A epidemiological evaluations were conducted
between 2008 and 2014 in 54 evaluation areas in 12
APOC countries, involving parasitological surveys in 639
sample villages where a total of 127 665 people were ex-
amined for the presence of O. v mf in the skin (Table 2).
Of the 54 evaluation areas, 21 were mesoendemic (max-
imum pre-control nodule prevalence between 21 and
42 %) and 32 hyperendemic (maximum nodule preva-
lence >42 %). On average some 12 villages were surveyed
per evaluation area. The median number of years of iver-
mectin treatment with at least 60 % reported treatment
coverage was 10 years, ranging from 3 years for two
areas in the Democratic Republic of Congo (where
ivermectin had been distributed for 8 to 10 years but
with insufficient treatment coverage for most years)
to 21 years for an area in Cameroon (Touboro) where
one of the first community trials of ivermectin was
done [47].
Compared to pre-control endemicity levels, the sur-
veys showed a major decline in infection levels. Overall
only 7.2 % of the examined persons were infected, the
CMFL was below 10 mf/s in all villages from evaluation
areas with more than 3 years adequate treatment (cover-
age ≥60 %) and in 20 evaluation sites all examined
people were skin snip negative.
In order to give a general appreciation of the observed
prevalence data for each evaluation area in relation to
model predictions, Fig. 3 shows the observed mf preva-
lences for the surveyed villages of each evaluation area
against the predicted trends. The main results are shown
in three graphs for three different ranges of pre-control
endemicity levels: high (CMFL >30mf/s), moderate (10<
CMFL ≤ 30 mf/s) and low (CMFL ≤10 mf/s). The results
for all surveyed villages in an evaluation area are dis-
played as one cluster in the graph corresponding to the
maximum pre-control endemicity level for those villages.
If the observed prevalence values for an evaluation area
are in agreement with the predictions, the maximum ob-
served prevalence of mf for the surveyed villages is ex-
pected to fall within the prevalence range predicted by
the model, while the observed prevalences for the other
surveyed villages of the evaluation area would have
lower values.
Figure 3a show the results for evaluation areas for
which the maximum pre-control endemicity level for the
surveyed villages was very high. The shaded band shows
for such high endemicity levels the range of predicted
mf prevalence after annual ivermectin treatment with
75 % treatment coverage. For most evaluation areas, the
survey data follow the predicted pattern with the highest
prevalences falling within the prediction band, and the
prevalences for less endemic villages falling below. There
are two exceptions. For the evaluation area of Ouaka in
the Central African Republic the observed prevalence
was zero in all surveyed villages which was much lower
than predicted. In the evaluation area of Touboro in
north Cameroon, the prevalence was higher than pre-
dicted in several villages.
Figure 3b shows the results for evaluation areas with
high endemicity levels (10< CMFL ≤30 mf/s). The overall
pattern is as predicted with the maximum prevalence for
most evaluation areas within the predicted band and the
maximum prevalence declining with number of years of
treatment. There are two evaluation areas where the
maximum prevalence exceeds the predicted value range.
After 12 years of treatment the observed prevalence is
zero in nearly all evaluation villages. The main exception
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Table 2 Results of phase 1A surveys and comparison of observed and predicted prevalences for each evaluation area
Country Evaluation
area
Maximum
pre-control
prevalence
of nodules
in evaluated
villages (%)
Treatment History Year of
evaluation
Comparison with Onchosim model predictions
Start year
of treatment
Treatment
rounds
with >60%
coverage
Number
of villages
surveyed
Number
of persons
examined
Number
mf positive
% mf
positive
Maximum
village
prevalence
of mf (%)
Maximum
village
CMFL
(mf/s)
Mean
village
prevalence
of mf (%)
Predicted
mean
prevalence
of mf (%)
Probability
that true
prevalence
<
predicted
prevalence
(Pl)
Probability
that true
prevalence
> predicted
prevalence
(PH)
Progress
towards
eliminationa
Burundi Cibitoke
Bubanza
49.1 2005 6 2012 10 3,424 0 0.0 0.0 0.0 0.0 17.5 1.000 0.000 ++
Cameroon Adamawa II 57.5 1999 9 2012 9 2,816 53 1.9 6.8 0.2 1.7 8.3 0.999 0.001 ++
Centre 1 71.9 2001 9 2011 12 2,576 1,377 53.5 71.6 5.3 52.3 31.0 0.000 1.000 −
Littoral 2 59.9 2000 9 2011 10 1,576 759 48.2 69.4 5.1 48.6 16.5 0.000 1.000 −
North
Tchollire
54.0 1999 10 2010 9 1,377 84 6.1 32.8 3.2 6.8 8.1 0.579 0.421 +
North
Toubouro
81.9 1989 21 2010 10 1,230 48 3.9 12.2 0.3 4.0 1.3 0.000 1.000 −
South West I 71.7 1999 10 2012 8 2,159 257 11.9 45.5 6.8 14.2 13.3 0.341 0.660 +
South West II 65.6 2001 8 2012 9 2,055 283 13.8 41.2 5.3 13.2 18.9 0.927 0.073 +
Western
Province
86.4 2001 8 2011 14 3,239 284 8.8 38.6 1.3 9.7 32.0 1.000 0.000 ++
CAR Basse-Kotto 59.7 1999 12 2010 9 2,758 41 1.5 3.8 0.1 1.6 8.6 1.000 0.000 ++
Ouaham
Pende
60.1 1999 15 2012 10 2,455 0 0.0 0.0 0.0 0.0 4.9 1.000 0.000 ++
Ouaka 64.6 1999 13 2012 9 2,443 0 0.0 0.0 0.0 0.0 2.3 0.996 0.004 ++
Chad Logon
Occidental
37.9 1998 11 2012 10 3,320 0 0.0 0.0 0.0 0.0 0.1 0.239 0.739 +
Logone
Oriental
62.8 1998 11 2012 19 4,403 5 0.1 2.1 0.0 0.1 1.0 0.883 0.117 +
Mayo Kebbi
East
45.2 1998 12 2013 5 1,660 0 0.0 0.0 0.0 0.0 0.1 0.295 0.553 +
Mayo Kebbi
West
44.4 1998 12 2013 18 6,425 1 0.0 0.3 0.0 0.0 0.1 0.227 0.772 +
Moyen-
Chari
40.1 1998 8 2009 9 1,337 0 0.0 0.0 0.0 0.0 3.4 0.997 0.003 ++
Congo Bouenza 28.3 2001 7 2011 10 1,585 13 0.8 5.6 0.0 0.7 8.4 1.000 0.000 ++
Pool 51.0 2004 7 2012 22 3,335 485 14.5 52.3 8.8 15.7 11.6 0.041 0.959 +
DRC Bas-Congo 65.9 2004 3 2012 22 4,823 2,140 44.4 71.3 9.8 40.5 49.3 0.989 0.011 ++
Sankuru 86.3 2003 3 2011 11 1,494 810 54.2 89.7 14.4 51.8 74.0 1.000 0.000 ++
Uélé 96.4 2002 5 2012 10 1,752 595 34.0 68.4 4.9 33.3 62.5 1.000 0.000 ++
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Table 2 Results of phase 1A surveys and comparison of observed and predicted prevalences for each evaluation area (Continued)
Ethiopia Kafa,Shekka,
Bench Maji
47.4 2001 7 2011 10 2,167 111 5.1 19.2 0.4 4.7 19.9 1.000 0.000 ++
North
Gondar
31.2 2003 7 2011 10 1,927 0 0.0 0.0 0.0 0.0 9.7 1.000 0.000 ++
Liberia Lofa, Bong,
Nimba
27.6 1999 5 2013 19 3,554 244 6.9 18.1 1.0 6.6 17.6 0.999 0.001 ++
Malawi Malawi
Extension
21.6 2000 7 2011 9 1,960 0 0.0 0.0 0.0 0.0 4.8 1.000 0.000 ++
Thyolo
Muanza
34.1 1999 7 2011 11 2,375 0 0.0 0.0 0.0 0.0 8.2 1.000 0.000 ++
Nigeria Adamawa 51.5 2001 11 2012 10 1,574 0 0.0 0.0 0.0 0.0 0.7 0.523 0.477 +
Cross river 56.1 1998 11 2009 20 3,583 81 2.3 8.3 0.5 2.4 3.0 0.430 0.570 +
Ebonyi 60.2 1999 11 2010 11 1,976 0 0.0 0.0 0.0 0.0 3.1 0.999 0.001 ++
Edo, Ondo 36.4 2001 8 2010 7 1,540 422 27.4 54.7 3.3 30.2 9.8 0.000 1.000 −
Ekiti 22.8 2000 12 2012 10 1,939 36 1.9 12.0 0.5 1.9 0.4 0.003 0.997 −
Enugu,
Anambra
63.0 1999 11 2011 11 2,396 86 3.6 13.7 0.2 3.6 4.5 0.602 0.398 +
FCT 21.1 1999 14 2013 10 1,385 2 0.1 2.9 0.0 0.3 0.1 0.029 0.966 +
Kaduna 55.8 1991 17 2008 29 5,988 0 0.0 0.0 0.0 0.0 0.1 0.041 0.959 +
Kano 26.0 2001 12 2013 12 1,820 0 0.0 0.0 0.0 0.0 0.4 0.262 0.738 +
Kebbi 21.5 2002 7 2013 7 1,365 0 0.0 0.0 0.0 0.0 3.8 1.000 0.000 ++
Kwara 32.2 1999 13 2013 12 2,013 29 1.4 11.2 0.5 1.3 0.3 0.001 0.999 −
Niger 28.7 2000 12 2013 15 2,820 0 0.0 0.0 0.0 0.0 0.6 0.459 0.541 +
Osun 25.6 1998 12 2012 11 1,544 0 0.0 0.0 0.0 0.0 1.5 0.882 0.118 +
Oyo 35.2 2000 9 2013 11 1,235 6 0.5 6.5 0.2 0.9 3.8 0.925 0.075 +
Plateau
Nassarawa
51.5 1998 14 2012 10 1,912 2 0.1 1.2 0.0 0.1 0.3 0.154 0.846 +
Taraba 61.8 1998 11 2009 10 1,695 214 12.6 60.8 4.6 16.9 6.3 0.000 1.000 −
Zamfara 12.8 2001 9 2010 7 1,007 0 0.0 0.0 0.0 0.0 1.2 0.835 0.165 +
Tanzania Kilosa 25.1 2002 10 2012 10 1,488 37 2.5 19.5 1.2 3.3 1.1 0.011 0.990 −
Mahenge 78.7 1998 7 2009 10 1,792 176 9.8 21.9 2.2 8.3 43.8 1.000 0.000 ++
Morogoro 35.7 2004 7 2013 20 3,406 169 5.0 33.7 3.4 6.1 8.2 0.727 0.273 +
Ruvuma 92.3 1999 10 2011 12 2,638 104 3.9 16.2 0.4 4.4 20.2 1.000 0.000 ++
Tanga 35.4 2000 9 2010 10 2,047 6 0.3 2.2 0.1 0.4 4.3 0.999 0.001 ++
Tukuyu 39.7 2001 10 2011 10 1,861 0 0.0 0.0 0.0 0.0 4.2 1.000 0.000 ++
Tunduru 58.0 1995 16 2013 10 1,832 0 0.0 0.0 0.0 0.0 0.3 0.331 0.669 +
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Table 2 Results of phase 1A surveys and comparison of observed and predicted prevalences for each evaluation area (Continued)
Uganda Kasese 45.5 1998 11 2010 10 1,510 51 3.4 12.1 0.1 3.1 4.6 0.651 0.349 +
Arua
Nebbie
87.3 1999 11 2009 21 3,894 90 2.3 32.1 1.0 3.8 10.5 1.000 0.000 ++
Adjumani
Mojo
34.9 1999 11 2010 9 1,180 35 3.0 6.7 0.0 2.5 1.4 0.036 0.964 +
Total 639 127,665 9,136 7.2 89.7 14.4 12.1
aDecline in prevalence of mf: ++ Faster: prevalence declining significantly faster than predicted (pL > 0.975)
+On track: prevalence not significantly lower or higher than predicted (pL < 0.975 and pH < 0.975)
-Delayed: prevalence declining significantly slower than predicted (pH> 0.975)
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Fig. 3 Observed mf prevalences in surveyed villages against predicted trends for three pre-control endemicity ranges: a. high (CMFL > 30mf/s),
b. moderate (10 mf/s < CMFL ≤ 30 mf/s) and c. low (CMFL ≤ 10 mf/s)
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to the overall pattern is the result for Cibitoke-Bubanza
in Burundi where the prevalence was already zero after
only 6 years of treatment, which is much faster than
predicted.
Figure 3c shows the results for the lowest endemicity
category (CMFL ≤10 mf/s). As predicted, the observed
prevalences were generally much lower than in the other
two endemicity categories. But there are several sites
where the observed prevalence was zero in all surveyed
villages after only 7 to 8 years of treatment, i.e. much
earlier than predicted. There are also two sites, Ekiti and
Kwara in Nigeria, where one village still had a preva-
lence of about 10 % after 10 years treatment.
In addition to the evaluation areas for which the re-
sults are shown in Fig. 3, there were six evaluation areas
for which there was evidence that treatment coverage
was much lower than reported. The results for these
sites are shown separately in Fig. 4. In all six sites the
observed data reflected the problems with treatment
coverage and the observed prevalences were much
higher than predicted if treatment coverage had been
75 %. In Centre 1 and Littoral 2 in Cameroon and Edo/
Ondo in Nigeria the observed prevalences for most sur-
veyed villages where even higher than the predicted
prevalence range. Follow-up investigations in these sites
showed much lower treatment coverage than reported
and in some years ivermectin had apparently not even
reached certain areas. In Taraba there was one major
outlier with 60 % prevalence for a village from a small
river valley that had been missed in the treatment pro-
gram. In Kilosa there was a single village with 20 %
prevalence and this village had not received treatment
during the first 3 years of the CDTi project. The project
of Sankuru in the Democratic Republic of Congo only
reported >60 % treatment coverage for 3 of the 8 years
of its existence but a local treatment coverage survey
showed that even in those 3 years the coverage had been
significantly lower than reported in half of the villages.
Table 2 shows the results of a detailed statistical com-
parison of the observed prevalence data with the corre-
sponding predicted prevalences taking the local pre-
control endemicity level, treatment coverage and dur-
ation of treatment into account. For 23 evaluation areas
the decline in the prevalence of onchocerciasis infection
was significantly faster than predicted. For another 23
evaluation sites the prevalence of infection was not sig-
nificantly different from predicted and their progress to-
wards elimination was classified as on track. Eight areas
showed delayed results with the prevalence declining
significantly slower than predicted. These include five of
the evaluation areas with evidence of unsatisfactory
treatment coverage shown in Fig. 4 (Centre 1, Littoral,
Taraba, Edo/Endo and Kilosa), as well as Touboro in
Cameroon (Fig. 3a) and Ekiti and Kwara in Nigeria
(Fig. 3c).
Results of phase 1B evaluations
Phase 1B epidemiological evaluations were conducted in
22 evaluation areas involving skin snip surveys in 392
villages where 108 636 people were examined for oncho-
cerciasis infection (Table 3). For 18 of these evaluation
areas, phase 1A results indicated that the prevalence of
mf had fallen below the threshold of 1.4 % (14 areas) or
was close to the threshold (four areas), justifying
Fig. 4 Observed mf prevalences for evaluation areas with evidence that treatment coverage was lower than reported
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Table 3 Results of phase 1B surveys and assessment if epidemiological criteria for stopping treatment are met
Country Evaluation
area
Pre-control
endemicity
(maximum
nodule
prevalence)
Results of Phase 1B surveys Results of all surveys combined
Phase 1B
Evaluation
year
No. of
treatment
rounds
with >60 %
coverage
No. of
villages
evaluated
Number
examined
for mf
mf positives No. of
villages
evaluated
Number
examined
for mf
mf positives Probability
that true
prevalence
of mf in
evaluation
area exceeds
1.4 %
Probability
that true
maximum
stratum
prevalence
of mf exceeds
5 %
Epidemiological
criteria for
stopping
treatment meta
Number % Maximum
% per
village
Number % Mean
% per
village
Maximum
% per
village
Burundi Bururi 31.0 2013 7 20 8,621 2 0.02 0.7 20 8,621 2 0.02 0.03 0.7 0.000 0.000 Yes
Cibitoke
Bubanza
49.1 2013 7 10 3,886 1 0.03 0.3 20 7,310 1 0.01 0.01 0.3 0.000 0.000 Yes
Rutana 24.6 2013 7 20 7,505 0 0.00 0.0 20 7,505 0 0.00 0.00 0.0 0.000 0.001 Yes
Chad Logon
Occidental
37.9 2014 13 9 2,360 0 0.00 0.0 19 5,680 0 0.00 0.00 0.0 0.000 0.000 Yes
Logon
Oriental
62.8 2014 13 43 9,624 33 0.34 11.9 62 14,027 38 0.27 0.36 11.9 0.000 1.000 Close
Mandoul 66.1 2013 12 32 12,812 28 0.22 3.4 32 12,812 28 0.22 0.26 3.4 0.000 0.205 Close
Mayo
Kebbi East
45.2 2014 13 25 7,648 0 0.00 0.0 30 9,308 0 0.00 0.00 0.0 0.000 0.006 Yes
Mayo
Kebbi
West
44.4 2014 13 16 6,660 0 0.00 0.0 34 13,085 1 0.01 0.01 0.0 0.000 0.000 Yes
Moyen-
Chari
40.1 2012 11 20 5,736 0 0.00 0.0 29 7,073 0 0.00 0.00 0.0 0.000 0.017 Yes
Tandjile 38.7 2013 12 29 8,414 3 0.04 0.7 29 8,414 3 0.04 0.03 0.7 0.000 0.008 Yes
Ethiopia North
Gondar
47.4 2013 9 20 2,986 0 0.00 0.0 30 4,913 0 0.00 0.00 0.0 0.000 0.009 Yes
Malawi Malawi
Extension
21.6 2012 8 12 2,220 29 1.31 8.7 21 4,180 29 0.69 0.46 8.7 0.012 0.997 Close
Thyolo
Muanza
34.1 2012 8 12 2,105 13 0.62 8.2 23 4,480 13 0.29 0.36 8.2 0.004 0.970 Close
Nigeria Cross River 56.1 2012 14 22 3,832 275 7.18 25.3 42 7,415 356 4.80 5.10 25.3 1.000 1.000 No
Ebonyi 60.2 2012 13 7 1,465 45 3.07 11.9 18 3,441 45 1.31 1.06 11.9 0.859 1.000 Close
Enugu
Anambra
63.0 2012 12 14 2,595 49 1.89 12.0 25 4,991 135 2.70 2.29 13.7 1.000 1.000 No
Kaduna 55.8 2012 21 17 2,600 0 0.00 0.0 46 8,588 0 0.00 0.00 0.0 0.000 0.033 Yes
Tanzania Tanga 35.4 2012 11 20 3,596 1 0.03 0.5 30 5,643 7 0.12 0.11 1.1 0.000 0.028 Yes
Tukuyu 39.7 2012 11 17 3,146 0 0.00 0.0 28 5,007 0 0.00 0.00 0.0 0.000 0.042 Yes
Tunduru 67.5 2013 16 10 1,379 0 0.00 0.0 20 3,211 0 0.00 0.00 0.0 0.000 0.020 Yes
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Table 3 Results of phase 1B surveys and assessment if epidemiological criteria for stopping treatment are met (Continued)
Uganda Adjumani
Mojo
45.5 2012 13 19 4,465 63 1.41 9.7 28 5,645 98 1.74 1.76 9.7 1.000 1.000 No
Kasese 87.3 2012 14 18 4,981 23 0.46 3.5 28 6,491 74 1.14 1.45 12.1 0.999 1.000 Close
Total 392 108,636 565 0.52 25.3 614 157,840 830 0.53 0.52 25.3
aCriteria met:
Yes: Probability <0.01 that the area prevalence exceeds 1.4 % and probability <0.05 that the maximum sample stratum prevalence exceeds 5 %
Close: Above probability thresholds not met but percentage mf positives <1.4 %
No: Above probability thresholds not met and percentage mf positives >1.4 %
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progression to phase 1B. In addition, there were four
evaluation areas (2 in Burundi and 2 in Chad) where no
phase 1A evaluations were done but for which APOC’s
Technical Consultative Committee recommended that
they move straight into phase 1B given that the phase
1A evaluations in the other evaluation areas in these
two countries had shown zero prevalence in all sur-
veyed villages.
The phase 1B surveys were done some 1 to 2 years
after the phase 1A surveys, and focused on remaining
sections of the evaluation area that had not yet been ad-
equately covered. Hence, the phase 1B surveys are com-
plementary to the phase 1A surveys and we have
therefore used the data from phase 1A and 1B combined
for the final analysis to determine whether the criteria
for stopping treatment were met.
Table 3 shows that 17 out of the 22 evaluation areas
meet the first criterion that the probability is <0.001 that
the overall prevalence of mf in the evaluation area should
exceeds 1.4 %. Only 13 evaluation areas also meet the sec-
ond criterion of having <0.05 probability that the max-
imum stratum prevalence of mf exceeds 5 %. Overall, 13
evaluation areas meet both criteria for stopping treatment,
three evaluation areas do not meet the criteria and six
evaluation areas are classified as “close”, i.e. they do not
yet meet the statistical criteria but they are close to elimin-
ation as reflected by the fact that the percentage of mf
positives in the total sample is less than 1.4 %.
Of the three evaluation areas that did not meet the cri-
teria, the results for Cross River in Nigeria were very
disappointing as the promising results from the phase
1A surveys were not confirmed: the overall percentage
of mf positives in the phase 1B surveys was 7.2 % (vs.
2.3 % in phase 1A surveys) and one phase 1B village
showed a prevalence of 25.3 %. Compared to the model
predictions, the 1B prevalences are now even higher
than predicted. In the other two evaluation areas the
prevalence of mf continued to decline between the two
phases but the phase 1B evaluation came too early and
some more years of treatment will be needed to achieve
elimination.
Table 4 summarises the results of the phase 1A and
phase 1B evaluations by country. In 36 evaluation areas
only phase 1A evaluations were done and 30 of those
showed satisfactory progress towards elimination. This
included 14 projects where less than 1.4 % of those ex-
amined were mf positive, and these projects were there-
fore classified as “close to elimination” and ready to
proceed to phase 1B. In most of these 14 projects no-
body was mf positive and these projects may already
have achieved elimination but this requires confirmation
in phase 1B surveys. In Burundi, Chad and Malawi all
evaluation areas had phase 1B evaluations and all were
classified having met the criteria for stopping treatment
or being close to elimination. Since these evaluation
areas covered all CDTi projects in these countries,
Table 4 Classification of the results of phase 1A and phase 1B evaluations by country
Country Total no. of
CDTi projects
in the country
Projects
evaluated
Evaluation areas with Phase 1A evaluation only Evaluation areas with phase
1B evaluation
Total
evaluation areas
Evaluation
areas
Close to
elimination
On track but still
some years to go
Delayed
decline in
prevalence
Evaluation
areas
Meets criteria for
stopping treatment?
Yes Close No
Burundi 3 3 3 0 - - - 3 3 0 0
Cameroon 15 8 8 8 0 5 3 0 - - -
CAR 1 1 3 3 2 1 0 0 - - -
Chad 1 1 7 0 - - - 7 5 2 0
Congo 2 2 2 2 1 1 0 0 - - -
DRC 20 3 3 3 0 3 0 0 - - -
Ethiopia 9 3 2 1 0 1 0 1 1 0 0
Liberia 3 1 1 1 0 1 0 0 - - -
Malawi 2 2 2 0 - - - 2 0 2 0
Nigeria 27 18 17 13 10 0 3 4 1 1 2
Tanzania 7 7 7 4 0 4 0 3 3 0 0
Uganda 5 3 3 1 0 1 0 2 0 1 1
Total 95 52 58 36 13 17 6 22 13 6 3
100.0 % 54.7 % 61.1 % 100.0 % 36.1 % 47.2 % 16.7 % 100.0 % 59.1 % 27.3 % 13.6 %
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nationwide elimination of onchocerciasis may already
have been achieved. This is reinforced in Burundi and
Chad by results of recent epidemiological assessments
for mapping outside the CDTi projects areas that
revealed 0 % mf prevalence in all the villages surveyed.
Table 5 summarises the main conclusions of the epi-
demiological evaluations. For 13 evaluation areas with a
population of 7 million the phase 1B evaluations showed
that the epidemiological criteria for stopping treatment
had been met. Another 20 evaluation areas with 21 mil-
lion people are close to elimination. Several of those
may already have achieved elimination but this still re-
quires confirmation in phase 1B surveys. Another 18
evaluation areas are on track but still require more years
of treatment to reach the elimination breakpoint. Overall
51 of 58 evaluation areas are making satisfactory pro-
gress. In seven areas the progress was unsatisfactory,
mainly as a result of poor treatment coverage. Figure 5
shows the location of the 58 evaluation areas and the
classification of their evaluation results.
Discussion
Control of public health problem
APOC’s original aim was to control onchocerciasis as a
public health problem. The results of the epidemio-
logical evaluations in 58 evaluation areas in 12 APOC
countries indicate that this has been largely achieved.
The infection level when onchocercal blindness starts to
become a public health problem has been defined by
Dadzie et al. as a CMFL of 10 mf/s [48]. Onchocercal
skin disease is also strongly correlated with endemicity
[7] but a threshold for its public health importance has
not been defined. The epidemiological evaluations
showed that the CMFL was below the threshold of 10
mf/s in all surveyed villages in all evaluation areas with
more than 3 years treatment. In two thirds of the evalu-
ation areas, the maximum CMFL had even fallen below
0.5 mf/s, i.e. a level where onchocercal blindness is not
known to occur [48]. Hence, in all evaluated areas with
more than 3 years treatment, including several areas
with unsatisfactory treatment coverage, the results
indicate that ocular onchocerciasis is no longer a public
health problem. Whether the same can be concluded for
the 54 ongoing CDTi projects of APOC that have not
yet been evaluated is not known. However, most of these
remaining projects have had more than 5–7 years iver-
mectin treatment with good reported coverage and, ex-
trapolating from the results for the evaluated areas, it is
likely that onchocerciasis is also no longer a public health
problem in those projects. For a few remaining projects
with poor treatment coverage, e.g. in Angola, South Sudan
and the Democratic Republic of Congo, it is less certain
that the disease has been controlled as a public health
problem and this requires further evaluation.
Progress towards elimination
The evaluation results showed that CDTi has achieved
much more than the control of a public health problem
and that most evaluation areas are making significant
progress towards elimination of onchocerciasis infection
and transmission. In 13 evaluation areas with a total at-
risk population of 7 million people, the epidemiological
evaluation data indicate that ivermectin treatment can
be stopped. It is noteworthy that in all but one of these
areas, the thresholds for stopping treatment were
reached after only 7 to 13 years of annual ivermectin
treatment, i.e. several years earlier than the 15 to 17 years
of annual treatment in the proof-of-principle study in
Mali and Senegal [23, 24]. Another 20 areas with 21 mil-
lion people are classified as being close to elimination.
This includes 10 areas with 11 million people for which
the phase 1A data suggest that the breakpoint has been
reached but which would still require phase 1B evalua-
tions to confirm that this is true for the whole evaluation
area. It also includes some projects for which the phase
1B results did not yet meet our strict statistical criteria
for elimination but for which the epidemiological results
were comparable to those in the proof-of-principle
study. In our opinion these areas warrant experimental
cessation of treatment, using the same methodology as
in the proof-of-principle study, in order to test whether
treatment can be safely stopped and strengthen the
Table 5 Overall classification of progress towards elimination in all 58 evaluation areas
Evaluation areas Population
Conclusion of the epidemiological evaluation No. % No. %
1. Satisfactory progress towards elimination
1.1 Meets criteria for stopping treatment 13 22.4 7,027,252 13.2
1.2. Close to elimination 19 32.8 18,355,590 34.5
1.3 On track but still some years to go 18 31.0 17,397,096 32.7
Subtotal satisfactory progress 50 86.2 42,779,938 80.5
2. Unsatisfactory progress 8 13.8 10,360,552 19.5
Total 58 100.0 53,140,491 100.0
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evidence base for elimination thresholds. Another 15
evaluation areas with 17 million people appear on track
to elimination but still require several more years of
treatment to reach the elimination thresholds. Overall
51 evaluation areas with 45 million people were making
satisfactory progress towards elimination.
Progress was not satisfactory in seven evaluation areas
with a population of 8 million people. The main reason
was poor treatment coverage which proved to be much
lower than reported in five areas as evidenced by the find-
ings of independent coverage surveys or local information
obtained by the survey teams. For these areas, the unsatis-
factory results concerned all surveyed villages and indi-
cated that the whole area was lagging behind. Major
improvements in implementation, supervision and moni-
toring, and many additional years of treatment will be
required to achieve elimination in these areas. The feed-
back of the unsatisfactory evaluation results to the CDTi
projects concerned has already produced dramatic im-
provements in treatment coverage for several of them.
Epidemiological modelling
In our analysis we have made extensive use of epidemio-
logical modelling for the interpretation of the epidemio-
logical evaluation data. Onchocerciasis models predict
that the declines in the prevalence and intensity of infec-
tion during long-term ivermectin treatment programmes
depend on the initial local endemicity level and ivermec-
tin treatment coverage [29, 34, 45]. The observed trends
in the prevalence of infection in the evaluated areas were
consistent with this. The prediction that the decline in
infection levels during onchocerciasis control depends
on the pre-control endemicity level has been previously
confirmed for vector control by the extensive longitu-
dinal evaluation data of the Onchocerciasis Control
Programme in West Africa [38]. The current results pro-
vide the first large-scale empirical confirmation that the
decline in infection levels after ivermectin treatment is
also strongly influenced by the initial endemicity levels.
In the areas with the highest pre-control endemicity
levels, there were, as predicted, still many villages with a
Fig. 5 Map of the APOC countries showing the location and classification of the 58 evaluation areas
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prevalence between 10 and 25 % after 10 years of treat-
ment while in the evaluation areas with the lowest en-
demicity levels the prevalence in nearly all evaluated
villages was 0 % after 10 years. Higazi et al. also reported
that the prevalence of mf as well as the vector infectivity
rate had fallen to insignificant levels after 10 years of
ivermectin treatment in a focus with a very low pre-
control endemicity level in Sudan where treatment was
given annually for the first 8 years and then at 6-
monthly intervals [49]. This effect of endemicity level
needed to be taken into account in the interpretation of
the evaluation results and we have therefore for each
surveyed village compared the observed prevalence with
the ONCHOSIM predicted prevalence after correcting
for the local pre-control endemicity level and treatment
coverage and taking statistical uncertainty into account.
This has enabled us to identify areas where the epi-
demiological evaluation results indicated satisfactory
progress towards elimination, and areas where the de-
cline in prevalence was slower than predicted.
Challenges for elimination
One of the areas with a slower-than-predicted decline in
prevalence was the Touboro focus in Cameroon for
which the highest pre-control nodule prevalence accord-
ing to the REMO map was 86 % which corresponds to a
CMFL of about 70 mf/s. However, during the pre-
control period there have been several parasitological
studies in this area showing some of the highest re-
corded onchocerciasis endemicity levels in the world,
with a pre-control CMFL as high as 303 mf/s in one vil-
lage near the border of Chad [47]. After 21 years of an-
nual ivermectin treatment, the average prevalence had
fallen to as low as 4 % and the maximum village preva-
lence and CMFL recorded as part of APOC surveys were
only 12 % and 0.27 mf/s in a village where one of the
pre-control parasitological surveys had shown a preva-
lence of 90.5 % and a CMFL 115.9 mf/s. That represents
an enormous reduction in infection from the extreme
levels of the pre-control period, but it is still significantly
higher than predicted for 21 years of annual treatment
with 72 % coverage at a pre-control CMFL of 70 mf/s,
i.e. the local endemicity level estimated from the nodule
prevalence map and the maximum endemicity level con-
sidered in the ONCHOSIM predictions. We have there-
fore done some ad hoc ONCHOSIM simulations for a
pre-control CMFL of 115 mf/s which indicated that the
observed prevalence data for Touboro after 21 years of
ivermectin treatment are still broadly consistent with
predictions. But it does raise the question of how many
years of treatment would be required in such extremely
endemic areas and whether annual treatment can ever
achieve complete elimination [50]. In such ‘holo-en-
demic’ areas the end-game might require alternative
strategies such as additional vector control or test and
treat strategies [51] where the relatively low number of
people remaining infected with O. volvulus would be
identified by rapid tests such as the LTS DEC-patch [52]
followed by skin snips to confirm a positive result and
treated with a macrofilaricidal regimen [53]. The analysis
has also allowed the identification of areas where the de-
cline in prevalence was faster than predicted. There were
several such areas which may indicate that the ONCHO-
SIM model, as currently quantified, somewhat underesti-
mates the long-term impact of ivermectin treatment.
The residual infection levels in Touboro also pose an-
other challenge. The focus lies along the Vina River,
close to the border with Chad. Downstream from the
Touboro focus, the Vina River runs along and then
across the border into an onchocerciasis area in Logone
Oriental in Chad for which the phase 1B evaluation data
indicate that it is close to elimination. However, there is
still one village with more than 10 % mf prevalence in
the evaluation area in Chad and that village lies along
the Vina River at 12 km from the border with
Cameroon. This situation provides a good example of
the challenge of onchocerciasis elimination in border
areas. Cross-border foci are common in Africa as rivers
often form natural borders between countries while they
provide also the breeding sites for the vector in oncho-
cerciasis endemic areas. Simulium damnosum s.l. is a
powerful fly that can travel many (and sometimes more
than 20) kilometres in search of a bloodmeal without re-
specting national boundaries, and elimination of oncho-
cerciasis in cross-border foci requires that infection
levels are brought down below the elimination threshold
on both sides of the border before treatment can be
stopped. Hence cross-border coordination and syn-
chronisation of treatment and evaluation activities is
critical for onchocerciasis elimination in such areas.
Cross-border foci are an issue for 23 of the 58 evaluation
areas, and they are therefore a major challenge for on-
chocerciasis elimination.
Stopping criteria and sampling strategy
For the analysis of the phase 1B data to determine
whether treatment could be stopped in an evaluation
area we used two statistical criteria that correspond to
the provisional epidemiological thresholds for treatment
interruption (pOTTIS) in APOC’s conceptual and oper-
ational framework of onchocerciasis elimination and that
take the sampling methodology into account. The sam-
pling used for the epidemiological evaluations was a
spatially stratified sampling method in which sample vil-
lages were selected at regular distances along the main
rivers and affluents throughout the evaluation area. Ac-
cording to the guidelines, villages were to be selected at
distances of no more than 20–30 km between villages.
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In practice, villages were selected at shorter distances
with an average distance of 8 km between neighbouring
villages. The rivers were thus divided into sections, or
strata, with an average length of 8 km and with one sam-
ple village located in the centre. The two statistical cri-
teria that we used to classify each evaluation area were
that the estimated area prevalence of mf should be less
than 1.4 % (with probability >0.99) and that the esti-
mated maximum stratum prevalence of mf should be
less than 5 % (with probability >0.95). Of the 21 areas
with phase 1B evaluations, 13 met both of these criteria,
5 failed both criteria and 4 evaluation areas in Malawi
and Chad had an estimated area prevalence below 0.5 %
but failed the maximum prevalence criterion because of
an elevated prevalence (between 3.4 and 11.9 %) for one
single phase 1B village in each evaluation area. This il-
lustrates that the criterion of an estimated maximum
stratum prevalence less than 5 % with more than 0.95
probability is a very strict criterion that requires the
observed prevalences to be very low throughout the
evaluation area. Compared to the survey data for the
proof-of-principle study in Mali and Senegal, where
there were several villages that did not meet the max-
imum prevalence criterion, this criterion may be too
strict. However, we consider it prudent to maintain this
criterion for routine use until further evidence becomes
available on the safety of stopping treatment in such
borderline situations.
One challenge for decision making to stop treatment
is to ensure there remain no pockets of residual infec-
tion which might lead to recrudescence of transmission.
Such pockets could be the result of villages having been
missed by the treatment programme or local problems
with treatment coverage that were not reported. As illus-
trated for the four evaluation areas in Malawi and Chad,
local pockets of infection could be missed if only the
overall prevalence criterion is used. We consider it
therefore important to also apply the second criterion
for the maximum prevalence and to use a stratified sam-
pling method that takes the transmission characteristics
of onchocerciasis into account by focusing on potential
high risk locations along rivers and ensuring a regularly
spaced sample throughout the evaluation area.
Purposive sampling of villages at high risk locations
along rivers has always been an essential part of the
sampling strategy for epidemiological evaluations of on-
chocerciasis control in Africa and we have also applied it
in our sampling strategy. Our stratified sampling ap-
proach assumes that the survey data for the sample vil-
lage in the centre of the river stratum represents the
highest risk for the stratum. This is true for isolated
areas where there is usually only one village per river
stratum. In other areas locally available entomological
data or remote sensing data on location of river rapids
were used to identify high risk locations near potential
vector breeding sites within each stratum and select the
nearest village for the sample. These villages were likely
to represent the maximum prevalence for the stratum
which is the information we are interested in. For the
remaining areas we selected one of the villages closest to
the river (previously referred to as 1st line villages [1]),
but there was no additional information available to
guide the selection of sample villages from the set of 1st
line villages. The length of river strata, with an average
of 8 km and an upper limit of 20 km, falls within the ac-
tive flight range of Simulium damnosum s.l. [54] and
any significant transmission along the river stretch
would most likely be reflected in the survey data for the
sample village in the centre of the stratum. However, the
prevalence for the surveyed village might in some cases
underestimate the stratum prevalence. We therefore rec-
ommend that river strata with the highest observed
prevalence of mf are also included in the entomological
evaluation to ensure that they do not constitute signifi-
cant pockets of transmission that pose a risk for recru-
descence. As mentioned before, the decision to stop
treatment requires both epidemiological and entomo-
logical evaluations. Because of the need for preparatory
activities such as training of entomological technicians
and prospection to identify vector collection sites, the
entomological evaluation took more time to get started
but in 2015 they were operational in several evaluation
areas. Though none have yet been completed, the pre-
liminary entomological data appear consistent with the
findings of the epidemiological evaluations.
Recent changes in guidelines for verifying onchocerciasis
elimination
WHO recently updated the original guidelines on certifi-
cation of elimination of human onchocerciasis that were
produced in 2001 [55]. The new guidelines document
that was published in January 2016 describes the recom-
mended verification process in phase 2 and phase 3, but
also addresses criteria and procedures for stopping mass
drug administration [56]. It recommends that only ento-
mological evaluation criteria and procedures, as de-
scribed above and employed by APOC, are used to make
the decision to stop treatment. However, when the num-
ber of collected blackflies is insufficient, epidemiological
evaluation data could be added using the OV16 serology
test in children below the age of 10 years (the document
notes that the recommendation to use OV16 is based on
low certainty of evidence). The aim of this serology test-
ing would be to provide information on exposure to
transmission over the preceding 10 years. This differs
from the evaluation methodology used by APOC where
entomological data are collected to measure transmis-
sion but where the epidemiological data measure current
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infection in the human population. The thresholds also
differ. The new guidelines recommend as the threshold
for stopping treatment an OV16 prevalence of 0.1 % in
children below the age of 10 years but it does not pro-
vide a rationale for this figure. An important priority for
further modelling research would be to clarify the rela-
tionship between different indicators and the risk of re-
crudescence after stopping treatment, and how this
varies with endemicity levels. This would help improve
decision-making on when to stop treatment which is
critically important: stopping too early may result in re-
crudescence but stopping too late may be very costly [2].
Another issue is whether a single antibody prevalence
from an area-wide random sample of children below the
age of 10 years, which is the age group at lowest risk in
onchocerciasis, would be able to detect residual pockets
of infection. Comparative studies of parasitology and
OV16 serology are currently ongoing in areas that are
close to elimination, and we hope that the results of
these studies will help to clarify this.
Conclusions
The control of onchocerciasis as a public health problem
has been virtually everywhere achieved: in the OCP coun-
tries in West Africa [6], in the OEPA countries in the
Americas [57] and now in the APOC countries, covering
all remaining onchocerciasis endemic countries in Africa.
The objective of large-scale ivermectin treatment is chan-
ging from onchocerciasis control to onchocerciasis elimin-
ation. In the Americas, onchocerciasis elimination with
ivermectin treatment has always been considered feasible
as most onchocerciasis foci in the Americas were small
and circumscribed, and most vector species relatively inef-
ficient [21]. Indeed, 6-monthly or even 3-monthly
ivermectin treatment has been able to interrupt transmis-
sion in most endemic areas in the Americas and several
American countries have recently verified nationwide
elimination of onchocerciasis based on the results of
post-treatment surveillance over a period of 3 years
which showed vector infectivity rates significantly
below the threshold of one infective fly per 2 000
flies tested [58–60]. But it has always been doubted
that onchocerciasis elimination with ivermectin treat-
ment would be feasible in Africa where onchocerciasis
was endemic over vast areas over millions of square
kilometres spanning 30 countries, with much higher
endemicity levels and highly efficient vectors that are
capable of migrating over hundreds of kilometres [21].
This perception started to change following the study in
Mali and Senegal which provided the proof-of-principle
that onchocerciasis elimination was feasible with both an-
nual and 6-monthly ivermectin treatment in at least some
endemic foci in Africa [23, 24]. The question became then
to what extent these results could be extrapolated to other
areas of Africa. The extensive epidemiological evaluation
results reported here for 12 APOC countries have shown
that all areas with adequate annual treatment coverage are
making satisfactory progress towards elimination and that
33 evaluation areas with a total population of 28 million
people are close to, or have already reached, elimination.
Hence, onchocerciasis elimination now appears feasible in
most, if not all, endemic areas in Africa.
The epidemiological evaluation results show great pro-
gress towards elimination and for many APOC countries
nationwide onchocerciasis elimination is clearly within
reach. However, to achieve this, much remains to be
done in terms of epidemiological and entomological
evaluations, cross-border coordination of treatment and
evaluation activities, acceleration of progress towards
elimination in areas that are lagging behind, operational
research on potential threats to elimination and alterna-
tive treatment strategies for holo-endemic and loiasis-
endemic areas etc. Unfortunately, APOC, that has been
effectively supporting and coordinating these activities,
was closed in December 2015 after having achieved its
original objective of establishing sustainable CDTi in all
endemic areas and controlling the disease as public
health problem. WHO is now putting into place a new
structure, the Expanded Special Project for the Elimin-
ation of Neglected Tropical Diseases, for coordinated
technical support for five neglected tropical diseases in
Africa that should also coordinate and support the
remaining onchocerciasis elimination activities in Africa
[61]. However, it is not clear if this initiative will receive
the necessary resources. Now that onchocerciasis control
and elimination have come so far, and so close to a def-
inite solution for most onchocerciasis endemic areas, we
sincerely hope that the endemic countries will maintain
the momentum, sustain high treatment coverage and allo-
cate substantial in-country resources for onchocerciasis
elimination activities and that the international commu-
nity will sustain its long-term commitment to onchocer-
ciasis control so that the job can be properly finished.
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